Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Phase 1 Recruiting 18 enrolled Weijia Fang, MD Chongqing Precision Biotech Co., Ltd · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.

Timeline

Start: 2024-07-24
Primary completion: 2026-06-01
Completion: 2027-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PTC13	Cell therapy	200000 cells/kg	Other
Subject	PTC13	Cell therapy	300000 cells/kg	Other
Subject	PTC13	Cell therapy	400000 cells/kg	Other
Subject	PTC13	Cell therapy	500000 cells/kg	Other

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Summary

Timeline

Drugs

Indications